ResMed Inc.’s Stock Price Soars to $242.25, Notching an Impressive 7.26% Uptick

ResMed Inc. (RMD)

242.25 USD +16.39 (+7.26%) Volume: 1.9M

ResMed Inc.’s stock price soars to 242.25 USD, marking a significant increase of +7.26% this trading session, with a strong trading volume of 1.9M. The company’s robust performance continues its upward trajectory with a +40.83% surge YTD, further solidifying its position in the market.

Latest developments on ResMed Inc.

ResMed Inc’s stock price experienced a 12% surge in the last quarter, reaching a new 12-month high at $232.65. Despite a slight fall on Monday, the stock continues to outperform the market. Analyst estimates and ratings are optimistic, with Zacks Research forecasting earnings of $2.02 per share in Q1 2025. SlateStone Wealth LLC has increased its stake in ResMed Inc, while Baillie Gifford & Co. holds a $10.06 million position in the company. Investors are advised to consider buying ResMed stock along with other top ASX 200 blue-chip shares.

ResMed Inc. on Smartkarma

Analysts on Smartkarma, like Baptista Research, are bullish on ResMed Inc. Recent research reports highlight the company’s strong performance in the fourth quarter of fiscal year 2024. ResMed achieved a 9% increase in revenue year-over-year, reaching $1.22 billion for the quarter. The company’s growth is attributed to increased demand, operational excellence, and a focus on innovations in sleep apnea, digital health solutions, and home medical equipment software.

Furthermore, ResMed’s latest products and their expected revenue impact are also a key focus for analysts. The company had a strong third financial quarter in 2024, showing robust top-line growth and double-digit bottom-line growth. This growth is driven by ongoing demand for their devices globally, strong growth in their Software as a Service business, and double-digit global growth in masks and accessories. Analysts are impressed with ResMed’s performance, especially considering the company is building on a previous year’s robust growth.

A look at ResMed Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

ResMed Inc. has received a mixed bag of Smart Scores, with high marks in Growth and Momentum but lower scores in Value and Resilience. The company’s strong momentum indicates positive market sentiment and potential for future growth, while its solid growth score suggests promising long-term prospects. However, the lower scores in Value and Resilience may raise some concerns for investors looking for stability and value in their investments.

Overall, ResMed Inc. seems to be on a positive trajectory with its high scores in Growth and Momentum, indicating a strong outlook for the company’s future performance. While the lower scores in Value and Resilience may warrant some caution, the company’s focus on developing and marketing medical equipment for sleep disordered breathing positions it well in a growing healthcare market. Investors may want to keep an eye on how ResMed Inc. navigates these factors in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma